DBV Technologies S.A. (DBVT) Income Statement Analysis

See more : DTCOM – Direct to Company S.A. (DTCY3.SA) Income Statement Analysis – Financial Results

Complete financial analysis of DBV Technologies S.A. (DBVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DBV Technologies S.A., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Southern Cross Electrical Engineering Limited (SXE.AX) Income Statement Analysis – Financial Results
Business Engineering Corporation (4828.T) Income Statement Analysis – Financial Results
Nexeon MedSystems Inc. (NXNN) Income Statement Analysis – Financial Results
Global Arena Holding Inc. (GAHC) Income Statement Analysis – Financial Results
Genting Plantations Berhad (2291.KL) Income Statement Analysis – Financial Results

DBV Technologies S.A. (DBVT)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.dbv-technologies.com

About DBV Technologies S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	15.73M	4.80M	5.71M	0.00	0.00	0.00	0.00	0.00	240.98K	332.67K	333.43K	297.52K	213.05K
Cost of Revenue	0.00	20.30M	9.27M	18.82M	3.09M	5.03M	3.43M	1.42M	152.70K	215.14K	187.74K	141.55K	109.96K
Gross Profit	15.73M	-15.50M	-3.57M	-18.82M	-3.09M	-5.03M	-3.43M	-1.42M	88.28K	117.54K	145.69K	155.96K	103.09K
Gross Profit Ratio	100.00%	-322.90%	-62.46%	0.00%	0.00%	0.00%	0.00%	0.00%	36.63%	35.33%	43.69%	52.42%	48.39%
Research & Development	60.22M	75.50M	70.34M	124.61M	129.00M	146.49M	148.13M	86.96M	40.84M	33.37M	31.85M	19.76M	11.28M
General & Administrative	25.16M	24.30M	30.52M	41.87M	55.77M	54.23M	49.85M	38.42M	20.03M	12.81M	11.57M	7.88M	4.05M
Selling & Marketing	-2.28M	1.60M	4.39M	12.12M	24.07M	43.97M	22.27M	12.45M	585.76K	0.00	0.00	0.00	0.00
SG&A	22.88M	25.90M	34.91M	53.98M	79.85M	98.20M	72.13M	50.86M	20.61M	12.81M	11.57M	7.88M	4.05M
Other Expenses	0.00	0.00	0.00	-12.67M	-16.04M	-17.52M	-16.17M	-9.82M	-7.03M	-7.18M	-6.68M	-4.44M	-2.95M
Operating Expenses	92.16M	101.40M	105.24M	165.92M	192.80M	227.17M	204.08M	128.00M	54.43M	39.00M	36.74M	23.20M	12.38M
Cost & Expenses	92.16M	101.40M	105.24M	165.92M	192.80M	227.17M	204.08M	128.00M	54.58M	39.22M	36.93M	23.34M	12.49M
Interest Income	3.78M	406.29K	440.79K	0.00	85.15K	673.86K	867.09K	1.67M	1.21M	1.15M	1.23M	883.09K	105.44K
Interest Expense	0.00	427.00K	583.77K	887.89K	1.79M	479.76K	4.68M	17.65K	174.18K	162.96K	44.59K	43.01K	72.00K
Depreciation & Amortization	-4.57M	20.30M	9.27M	18.82M	3.09M	5.03M	3.43M	1.42M	1.28M	813.52K	625.73K	480.40K	288.18K
EBITDA	-87.46M	-76.68M	-79.77M	-162.74M	-181.37M	-206.16M	-176.90M	-126.29M	-53.62M	-36.00M	-29.56M	-21.68M	-11.88M
EBITDA Ratio	-556.11%	-2,012.50%	-1,759.90%	0.00%	0.00%	0.00%	0.00%	0.00%	-21,512.88%	-11,099.55%	-10,418.58%	-7,286.80%	-5,575.59%
Operating Income	-76.43M	-96.63M	-98.61M	-194.80M	-192.80M	-227.17M	-204.08M	-128.00M	-54.34M	-38.89M	-36.59M	-23.04M	-12.27M
Operating Income Ratio	-485.97%	-2,013.15%	-1,727.65%	0.00%	0.00%	0.00%	0.00%	0.00%	-22,547.53%	-11,689.15%	-10,974.91%	-7,745.10%	-5,760.35%
Total Other Income/Expenses	3.71M	431.00K	8.99M	-24.67M	9.20M	15.56M	19.85M	1.66M	1.04M	986.34K	1.19M	840.08K	33.44K
Income Before Tax	-72.72M	-96.20M	-98.19M	-195.69M	-194.51M	-226.98M	-207.90M	-126.35M	-53.30M	-37.90M	-35.41M	-22.20M	-12.24M
Income Before Tax Ratio	-462.35%	-2,004.17%	-1,720.22%	0.00%	0.00%	0.00%	0.00%	0.00%	-22,116.35%	-11,393.08%	-10,619.61%	-7,462.73%	-5,744.65%
Income Tax Expense	7.00K	100.00K	-381.00K	-12.26K	692.67K	20.50K	1.41K	1.67M	1.21M	1.15M	1.23M	883.08K	105.44K
Net Income	-72.73M	-96.30M	-97.81M	-195.68M	-195.20M	-227.00M	-207.90M	-126.35M	-53.30M	-37.90M	-35.41M	-22.20M	-12.24M
Net Income Ratio	-462.40%	-2,006.25%	-1,713.54%	0.00%	0.00%	0.00%	0.00%	0.00%	-22,115.85%	-11,393.08%	-10,619.61%	-7,462.73%	-5,744.65%
EPS	-2.84	-4.96	-7.12	-14.48	-21.12	-31.40	-33.60	-20.68	-9.92	-9.44	-10.40	-7.24	-3.65
EPS Diluted	-2.84	-4.96	-7.12	-14.48	-21.12	-31.40	-33.60	-20.68	-9.92	-9.44	-10.40	-7.24	-3.65
Weighted Avg Shares Out	23.78M	19.35M	13.77M	13.52M	9.25M	7.23M	6.18M	6.11M	5.37M	4.02M	3.40M	3.07M	3.35M
Weighted Avg Shares Out (Dil)	23.78M	19.35M	13.77M	13.52M	9.25M	7.23M	6.19M	6.11M	5.38M	4.02M	3.40M	3.08M	3.35M

DBV Technologies To Conduct New Pivotal Trial For Peanut Allergy Patch, Shares Plunge To 52-Week Low

December 21, 2021benzinga.com

After reviewing the FDA's information requests and considering all other options, DBV Technologies (NASDAQ: DBVT) has decided not to pursue the sequential approach to develop Viaskin Peanut (allergen uptake/transport study before STAMP). DBV estimates that heeding to the FDA's newly proposed sequential approach would...

DBV Technologies to Participate in an Upcoming Investor Conference

November 24, 2021globenewswire.com

Montrouge, France, November 24, 2021

Down 42.6% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

November 17, 2021zacks.com

DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted.

Why DBV Technologies Stock Is Jumping Today

November 1, 2021fool.com

The company plans to announce new data for its experimental peanut allergy drug this week.

Down 36.6% in 4 Weeks, Here's Why You Should You Buy the Dip in DBV Technologies S.A. (DBVT)

November 1, 2021zacks.com

DBV Technologies S.A. (DBVT) is technically in oversold territory now, so the heavy selling pressure might have exhausted.

DBV Technologies Shares Down On FDA Update For Its Peanut Allergy Program

October 27, 2021benzinga.com

DBV Technologies (NASDAQ: DBVT) has received communication from the FDA concerning the STAMP protocol submission for its modified Viaskin Peanut (mVP) development program. The agency would like to review DBV's protein uptake release study data before providing additional comments on the STAMP protocol...